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PRESENTATION OF THE CASE
A 61-year-old man undergoes a sigmoid colectomy for a T3N1 (two of 18 nodes) adenocarcinoma of the sigmoid
colon. He recovers well and receives 6 months of adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)
uneventfully. At his first follow-up visit, the oncologist recommended every 3 month visits for a physical, liver func-
tion tests, and carcinoembryonic antigen (CEA) measurement; every 6 month chest, abdomen, and pelvic computed
tomography (CT) scans for 3 years; and aspirin, vitamin D supplementation, and exercise. Is CT scanning appro-
priateinthefollow-upofcoloncancerpatients?(ThiscasewaspresentedatMassachusettsGeneralHospitalCancer
Center.)
PRO
By Richard M. Goldberg
University of North Carolina at
Chapel Hill
Justrecently,Ireorganizedmytalking
points about management of meta-
static colorectal cancer. Now I focus
those conversations, whether they oc-
cur in a lecture hall or a clinic exam
room, around an AJCC (American Joint Committee on
Cancer) unsanctioned but pragmatic new staging system,
whichIwillcall“UNC.”Withmultidisciplinaryinputatthe
University of North Carolina (also, by coincidence, UNC),
we sort patients into those “unlikely (U)” to undergo resec-
tionbecauseoftheextentoftheirmetastaticdiseaseortheir
comorbid conditions that make the risk of surgery prohibi-
tive,thosewhocanundergoresection“now(N),”and,those
who “could (C)” after a response to medical treatment po-
tentially undergo resection. We formulate management
strategies that differ according to those categories. Cur-
rently, multidisciplinary teams can realistically offer the
possibility of long-term disease-free survival to a subset of
patients who fit into the N or C subcategories. How do we
segregate patients into those categories? We book them an
appointmentforaCTscanbecausetheyseldomhavesymp-
tomsorphysicalfindingsthatreliablytellushowextensive
their disease is [1].
After patients with stage II or III disease complete their
initial therapy, it is common practice to do interval CT
scans, CEAs, and colonoscopies aimed at early detection
CON
By David P. Ryan
Massachusetts General Hospital
In medicine, we are taught to, above
all, do no harm. My best friend and
fellow chief resident in the mid-1990s
at Columbia-Presbyterian Medical
Center, Mat Maurer, summed it up
best with his Golden Rule of Internal Medicine. There are
onlythreereasonstorecommendanythingtoapatient:tobe
cured,tolivelonger,andtofeelbetter.I’vekeptthisGolden
Rule in mind particularly when it involves recommending
chemotherapy in any setting. As post-treatment surveil-
lancebecomesanincreasingcomponentofourprofessional
lives, it’s worth applying this Golden Rule to seemingly in-
nocuous recommendations such as vitamin D, aspirin, ex-
ercise, and, as our fellow asked, CT scans.
Let’s start with the latter part of the Golden Rule. The
practice of getting CT scans in the post-adjuvant surveil-
lance period started in the 1990s for unclear reasons. It
probablywasanextensionofthemarketingpushtogetpeo-
ple to have colonoscopies so that we can “pick up cancer
early.” So, picking up metastatic cancer early must be a
good thing, right? Unknown. There is no level 1 evidence
showing that starting chemotherapy earlier for asymptom-
atic metastatic disease helps people live longer or feel bet-
ter. In fact, many of us are proponents of chemotherapy
holidays interspersed throughout the course of care for our
patients with metastatic colon cancer. The number one
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The Oncologist 2011;16:254–256 www.TheOncologist.comof recurrent disease and new primary tumors. Guidelines
issued by the American Society of Clinical Oncology
(ASCO), the National Comprehensive Cancer Network
(NCCN), and the Cochrane Collaboration reinforce this
practice [2–4]. Are we fooling ourselves and our patients
about the value of this approach in terms of lives saved or
prolonged and money spent? My fiscally conservative
crimson (Harvard’s colors) friend and colleague Dr. Ryan
suggests that we are and, from my vantage point on the op-
posite side of the color wheel (UNC’s team color is sky
blue), I disagree. Is there evidence on which to base a CT
scan-based surveillance protocol?
The natural history of colorectal cancer stands out
among solid tumors. Cohen and colleagues studied circu-
lating tumor cells (CTCs) in patients with metastatic dis-
ease, proving that with current technology they could
readilyidentifyCTCsina10-mlaliquotofblood[5].Yetin
manypatients,mostofthesepotentialseedsnevergrowand
scansdetectoneorafewmetastaticlesions.Inpatientswith
pancreaticcancer,resectionofmetastasesisnotcurative.In
many series, resection of limited hepatic and pulmonary
metastases in colorectal cancer patients leads to a 30%–
60% likelihood of long-term disease-free survival and to a
substantial 5-year survival rate, even when surgery and
drug therapy prove not to be curative [6]. Unfortunately, a
substantial number of patients will subsequently relapse,
some rapidly, and we need to discover molecular/genetic
profilesthatcanhelppredictwhoamongthepatientswitha
singleorsmallnumberofscan-identifiedlesionswilllikely
benefit from curative resection and who will not. We hope-
fully can spare patients the pain and society the expense of
fruitless surgeries once those data are available.
An expert multidisciplinary committee that included
several individuals whose prior published work included
recommendationsagainstroutinesurveillanceCTscanning
(Loprinzi, Virgo) wrote the most recent 2005 ASCO guide-
lines that endorse follow-up CT scan screening for patients
with stage II and III colorectal cancer [2]. An exhaustive
review of the literature available at that time convinced the
panelofthevalueofscans.Thereviewincludedthreemeta-
analyses, all of which they classified as “highest quality”
using the metrics defined by the Oxmann-Guyatt Overview
Quality Questionnaire. These three meta-analyses reported
a20%–33%reductionintheriskofdeathfromallcausesin
thegroupsofpatientswhohadscansasaroutinepartoffol-
low-up [4, 7, 8]. Interestingly, this reduction in the odds of
deathisnearlyidenticaltothatreportedbyMoertelandcol-
leagues for adjuvant therapy of stage III colon cancer [9].
Thedataonthebenefitofaddingoxaliplatintofluorouracil-
based therapy provides a lesser incremental benefit [10].
Presumably, Dr. Ryan does offer adjuvant therapy with
predictor of survival is sensitivity to chemotherapy, not
how early one receives it.
The crux of the argument for CT scans involves the first
part of the Golden Rule. Approximately 30% of patients
withmetastaticcoloncancercanbecuredbysurgicalresec-
tion if the disease is isolated to the liver or lung when it re-
curs. Is it reasonable to presume that we can pick up more
isolated disease by CT scanning? There have been three
randomized studies of postoperative surveillence CT scans
[1–3]. None of these studies demonstrated a statistically
significant survival advantage, but all were done in the era
prior to the understanding that isolated disease was poten-
tially curable. There have been two meta-analyses of stud-
ies that compared intensive surveillance strategies,
including the CT studies mentioned above with lax surveil-
lancestrategies[4,5].Theydemonstratedastatisticallysig-
nificant advantage in terms of mortality for intensive
follow-up.Giventhenumberofdesignflawsintheindivid-
ual studies that made up the meta-analyses, this was really
making lemonade out of lemons.
A retrospective analysis recently contributed to the ar-
gument in favor of CT scans. Chau and colleagues demon-
strated that patients with metastatic disease picked up by
CT scan as opposed to CEA measurement or symptoms
were more likely to be operated on for cure and were more
likely to survive [6]. Despite the retrospective nature and
the tremendous opportunity for bias, particularly in an era
when not all oncologists agree on resecting metasatic colon
cancer with curative intent, the ASCO guidelines now rec-
ommend yearly chest, abdomen, and pelvic CT scans in the
postoperative setting.
The cost in terms of toxicity may not be trivial. The in-
cidenceofcontrastallergicreactionsislow,butcontrastne-
phropathy can occur in up to 2% of cases and there may be
toxicity from cumulative radiation exposure [7, 8]. In addi-
tion, the cost of getting just the three CT scans for the ap-
proximately 50,000 people in the U.S. is nearly 120 million
dollars. This does not take into account the need to get end-
less3monthfollow-upCTsormagneticresonanceimaging
(MRI) scans for the “ditzel” that gets picked up in liver,
lungs, or marginally enlarged lymph nodes. Finally, the
added anxiety to the patient goes unmeasured.
But, let’s assume that CT scans work at curing patients.
For every 100 patients with stage 3 disease, 70 are cured.
For the 30 that present with metastatic disease, three to six
(10%–20%) present with isolated disease and are candi-
dates for resection already. For the 24 to 27 (80%–90%)
whopresentwithunresectabledisease,let’sassumethatthe
impact of CT scans is robust, as was seen in the Chau et al.
[6] study and converts nine (30%) to resectable by picking
upthediseaseearlier.Becausewecancureonly30%ofpa-
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resection. Finally, I am having a hard time with the validity
ofthecostestimatesthatDr.Ryanoffers.Insummary,Ibe-
lievethedatasupportCTscansurveillanceforpatientswith
stage II or III colorectal cancer and the management of
those patients found to have recurrent disease using the
“UNC” approach.
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tients with isolated disease, at most three extra people will
be cured of every 100 with stage 3 disease. If one takes into
account the added MRIs, positron emission tomography
(PET)scans,andsurgeries,it’seasytoassumethattheprac-
tice of getting CT scans costs millions of U.S. dollars for
every life that is theoretically saved.
So, does CT scanning in the postoperative surveillance
period meet the Golden Rule? I say “no”; but, even if it
does, at what cost?
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